148 related articles for article (PubMed ID: 29727784)
1. A risk prediction model for medical treatment failure in tubal pregnancy.
Lee JH; Kim S; Lee I; Yun J; Yun BH; Choi YS; Lee BS; Seo SK
Eur J Obstet Gynecol Reprod Biol; 2018 Jun; 225():148-154. PubMed ID: 29727784
[TBL] [Abstract][Full Text] [Related]
2. Predictors of methotrexate treatment failure in ectopic pregnancy.
Dilbaz S; Caliskan E; Dilbaz B; Degirmenci O; Haberal A
J Reprod Med; 2006 Feb; 51(2):87-93. PubMed ID: 16572908
[TBL] [Abstract][Full Text] [Related]
3. Role of initial and day 4 human chorionic gonadotropin levels in predicting the outcome of single-dose methotrexate treatment in women with tubal ectopic pregnancy.
Ustunyurt E; Duran M; Coskun E; Ustunyurt ÖB; Simşek H
Arch Gynecol Obstet; 2013 Nov; 288(5):1149-52. PubMed ID: 23666603
[TBL] [Abstract][Full Text] [Related]
4. The optimal cutoff serum level of human chorionic gonadotropin for efficacy of methotrexate treatment in women with extrauterine pregnancy.
Sagiv R; Debby A; Feit H; Cohen-Sacher B; Keidar R; Golan A
Int J Gynaecol Obstet; 2012 Feb; 116(2):101-4. PubMed ID: 22093497
[TBL] [Abstract][Full Text] [Related]
5. Predictors of success with methotrexate treatment of tubal ectopic pregnancy at Grady Memorial Hospital.
Potter MB; Lepine LA; Jamieson DJ
Am J Obstet Gynecol; 2003 May; 188(5):1192-4. PubMed ID: 12748475
[TBL] [Abstract][Full Text] [Related]
6. Multidose Methotrexate Treatment of Ectopic Pregnancies with High initial β-Human Chorionic Gonadotropin: Can Success Be Predicted?
Tug N; Sargin MA; Yassa M
Gynecol Obstet Invest; 2019; 84(1):56-63. PubMed ID: 30099453
[TBL] [Abstract][Full Text] [Related]
7. The predictors of successful methotrexate treatment of tubal ectopic pregnancy.
Abdelfattah-Arafa E; Abdussalam HF; Omar Saad M; El Ansari W
J Obstet Gynaecol; 2024 Dec; 44(1):2361456. PubMed ID: 38864434
[TBL] [Abstract][Full Text] [Related]
8. Medical management of ectopic pregnancy with single-dose and 2-dose methotrexate protocols: human chorionic gonadotropin trends and patient outcomes.
Mergenthal MC; Senapati S; Zee J; Allen-Taylor L; Whittaker PG; Takacs P; Sammel MD; Barnhart KT
Am J Obstet Gynecol; 2016 Nov; 215(5):590.e1-590.e5. PubMed ID: 27371354
[TBL] [Abstract][Full Text] [Related]
9. A new predictive scoring system including shock index for unruptured tubal pregnancy patients.
Kahyaoglu S; Turgay I; Gocmen M; Sut N; Batioglu S
Eur J Obstet Gynecol Reprod Biol; 2006 May; 126(1):99-103. PubMed ID: 16246482
[TBL] [Abstract][Full Text] [Related]
10. Risk factors and human chorionic gonadotropin trends in patients with ruptured tubal ectopic pregnancies despite methotrexate treatment.
Hutchinson AP; Pereira N; Chung ER; Shah NJ; Zeku M; Chung PH; Rosenwaks Z
Gynecol Endocrinol; 2019 Jan; 35(1):49-52. PubMed ID: 30322280
[TBL] [Abstract][Full Text] [Related]
11. Expectant management of tubal pregnancies with human chorionic gonadotropin up to 2000 mIU/mL.
Kugelman N; Cohen B; Yossef F; Margieh N; Regev N; Shani U; Bart Y
Int J Gynaecol Obstet; 2024 Mar; 164(3):1094-1100. PubMed ID: 37776069
[TBL] [Abstract][Full Text] [Related]
12. Day 1 to day 4 serum hCG change in predicting single-dose methotrexate treatment failure for tubal ectopic pregnancies.
Goh A; Karine P; Kirby A; Williams C; Kapurubandara S
Eur J Obstet Gynecol Reprod Biol; 2020 Dec; 255():105-110. PubMed ID: 33113399
[TBL] [Abstract][Full Text] [Related]
13. [Drug treatment of tubal pregnancy with methotrexate, with an analysis of 5 cases].
Dimitrova E; Milchev N; Krumov G; Paskaleva V; Velchev G
Akush Ginekol (Sofiia); 2002; 41(2):28-9. PubMed ID: 12066547
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of expectant management versus methotrexate in tubal ectopic pregnancy: a double-blind randomized trial.
Silva PM; Araujo Júnior E; Cecchino GN; Elito Júnior J; Camano L
Arch Gynecol Obstet; 2015 Apr; 291(4):939-43. PubMed ID: 25315383
[TBL] [Abstract][Full Text] [Related]
15. Cut-off value of initial serum β-hCG level predicting a successful MTX therapy in tubal ectopic pregnancy: a retrospective cohort study.
Helmy S; Bader Y; Pablik E; Tiringer D; Pils S; Laml T; Kölbl H; Koch M
Eur J Obstet Gynecol Reprod Biol; 2014 Aug; 179():175-80. PubMed ID: 24956362
[TBL] [Abstract][Full Text] [Related]
16. Methotrexate treatment for tubal pregnancy. Criteria for medical approach.
Cobellis G; Pierno G; Pecori E; Scaffa C; Stradella L; Messalli EM; Festa B; Cobellis L
Minerva Ginecol; 2003 Dec; 55(6):531-5. PubMed ID: 14676743
[TBL] [Abstract][Full Text] [Related]
17. ACOG practice bulletin. Medical management of tubal pregnancy. Number 3, December 1998. Clinical management guidelines for obstetrician-gynecologists. American College of Obstetricians and Gynecologists.
Int J Gynaecol Obstet; 1999 Apr; 65(1):97-103. PubMed ID: 10390113
[TBL] [Abstract][Full Text] [Related]
18. Ectopic pregnancy; risk factors and comparison of intervention success rates in tubal ectopic pregnancy.
Kazandi M; Turan V
Clin Exp Obstet Gynecol; 2011; 38(1):67-70. PubMed ID: 21485731
[TBL] [Abstract][Full Text] [Related]
19. Predictors of success of methotrexate treatment in women with tubal ectopic pregnancies.
Mol BW; Hajenius PJ; van der Veen F
N Engl J Med; 2000 Apr; 342(15):1138. PubMed ID: 10766587
[No Abstract] [Full Text] [Related]
20. [Medical treatment of unruptured ectopic pregnancy].
Rojas Mora E; Hernández Vivar LE; Sánchez Contreras J; Risco Cortés RJ; Pulido Olivares VH
Ginecol Obstet Mex; 2004 Apr; 72():135-41. PubMed ID: 15318753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
